Synapticure, Inc.Summer 2020Active☆Watch⊞Compare

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Synapticure, Inc. is one of 233 Biotech companies tracked from CHICAGO, IL, USA; Remote, on record since 2022. By capital raised it ranks among the largest (ahead of 96% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

We deliver personalized medicine for neurodegenerative patients

Personalized virtual clinical care is finally here for neurodegenerative diseases like Alzheimer's and related Dementias (Cognitive), Parkinson's and Huntington's (Movement), and ALS (Motor neuron). We provide a novel approach to care in these diseases, centering a patient and caregiver around a coordinator who quarterbacks patients through our full Multi-Disciplinary Care Resources to local aid, PT/OT and home health support. When you leave our clinic, it's not with a handful of paper referrals, but with our coordinators helping you book and find the best physicians, DME, trials, and even cheapest prescriptions. We are devoted to helping patients, from guidance on care and insurance to providing the full spectrum of investigational and clinical testing to improve outcomes. Synapticure was built by leading patient and caregiver advocates alongside leading clinicians, biotech executives and telemedicine executives to bring the neurodegenerative disease care and treatment experience into the 21st century, and is backed by the leading Venture funds and investors in the remote health and life sciences space.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Round size and date are reported; the stage label is inferred from round size (latest is Series C — a $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 96% of sector peers (real $). Modeled value above 96% of peers (estimate).

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

1. Series C$40.1M2024-09-09
   • First recorded raise — entered as Series C.
   • 51 investors on this round.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

Synapticure, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Synapticure, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Synapticure, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.